VALUE LINE Monthly
NVIV Daily - InVivo Therapeutics
"We are initiating coverage an establishing a near-term target of $4.50 per share based on DCF (rounding up slightly from the DCF). However, with the financing risk out of the way, perhaps later this year, and clear momentum on the clinical front, we think InVivo can trade as high as $7 per share on speculation of a take-out."
- Zacks Investment Research